Wall Street Associates’s Juno Therapeutics, Inc. JUNO Stock Holding History

Wall Street Associates’s Portfolio JUNO Stock Details JUNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-5,000	Closed	-$267K	–	367
2015 Q2	$267K	Hold	5,000	–	–	0.03%	325
2015 Q1	$303K	Sell	5,000 -5,000	-50%	-$243K	0.03%	301
2014 Q4	$522K	Buy	+10,000	New	+$448K	0.05%	250

Other funds holding JUNO

Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

GAMA

Graticule Asia Macro Advisors New York $649M AUM

Wall Street Associates's JUNO Position: Q3 2015 in Review

Wall Street Associates sold out of Juno Therapeutics, Inc. (JUNO) in Q3 2015, closing a stake of 5,000 shares — an estimated $267K sold.

Wall Street Associates first reported a position in JUNO in Q4 2014 and held it in 3 quarters. The position peaked at $522K in Q4 2014. 132 funds tracked by Wall St. Rank hold JUNO as of Q3 2015.

Wall Street Associates reported no remaining Juno Therapeutics, Inc. position as of Q3 2015 after selling out during the quarter.
Wall Street Associates sold 5,000 Juno Therapeutics, Inc. shares in Q3 2015, an estimated $267K.
Wall Street Associates first reported a position in Juno Therapeutics, Inc. in Q4 2014 and held it in 3 quarters.
Wall Street Associates's Juno Therapeutics, Inc. position peaked at $522K in Q4 2014.
132 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q3 2015.

Based on Wall Street Associates's 13F filing for Q3 2015, filed 12 Nov 2015.